Arab Board Oncology Part 1

Arab Board Medical Oncology Primary (Part 1) Written Exam (ABHS)

Targeted And ImmunotherapyEnglish
Exam overview

Practice session

Osimertinib is a 3rd-generation EGFR tyrosine kinase inhibitor (TKI) designed to overcome which specific secondary acquired resistance mutation that arises in patients treated with 1st-generation EGFR TKIs (gefitinib/erlotinib)?

Loading your practice session…